%0 Journal Article
%T Effects of tamoxifen on vaginal blood flow and epithelial morphology in the rat
%A Noel N Kim
%A Miljan Stankovic
%A Abdullah Armagan
%A Tulay T Cushman
%A Irwin Goldstein
%A Abdulmaged M Traish
%J BMC Women's Health
%D 2006
%I BioMed Central
%R 10.1186/1472-6874-6-14
%X Female Sprague-Dawley rats were subjected to sham surgery or bilateral ovariectomy. After 2 weeks, sham-operated rats were implanted with subcutaneous osmotic infusion pumps containing vehicle (control) or tamoxifen (150 ¦Ìg/day). Ovariectomized rats were similarly infused with vehicle. After an additional 2 weeks, vaginal blood flow responses to pelvic nerve stimulation were measured by laser Doppler flowmetry and vaginal tissue was collected for histological and biochemical assay.Tamoxifen treatment did not change plasma estradiol concentrations relative to control animals, while ovariectomized rats exhibited a 60% decrease in plasma estradiol. Tamoxifen treatment caused a significant decrease in mean uterine weight, but did not alter mean vaginal weight. Vaginal blood flow was significantly decreased in tamoxifen-infused rats compared to controls. Similar to ovariectomized animals, estrogen receptor binding was increased and arginase enzyme activity was decreased in tamoxifen-infused rats. However, different from control and ovariectomized animals, the vaginal epithelium in tamoxifen-infused rats appeared highly mucified. Periodic acid-Schiff staining confirmed a greater production of carbohydrate-rich compounds (e.g. mucin, glycogen) by the vaginal epithelium of tamoxifen-infused rats.The observations suggest that tamoxifen exerts both anti-estrogenic and pro-estrogenic effects in the vagina. These physiological alterations may eventually lead to vaginal atrophy and compromise sexual function.Tamoxifen is a non-steroidal, triphenylethylene derivative that is widely used and highly effective as adjuvant therapy for the management of breast cancer patients with estrogen receptor (ER) positive tumors. Originally developed in the 1960s as a contraceptive agent, tamoxifen was later found to stimulate ovulation, as well as inhibit the formation of mammary tumors in rats exposed to carcinogens [1]. While tamoxifen itself is a poor ER ligand, its metabolite 4-hydroxytamo
%U http://www.biomedcentral.com/1472-6874/6/14